On Monday, Enliven Therapeutics Inc (NASDAQ: ELVN) was -4.74%% drop from the session before settling in for the closing price of $21.3. A 52-week range for ELVN has been $13.30 – $30.03.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 19.02%. When this article was written, the company’s average yearly earnings per share was at -15.53%. With a float of $38.76 million, this company’s outstanding shares have now reached $49.04 million.
Let’s determine the extent of company efficiency that accounts for 62 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Enliven Therapeutics Inc (ELVN) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Enliven Therapeutics Inc stocks. The insider ownership of Enliven Therapeutics Inc is 34.29%, while institutional ownership is 61.32%. The most recent insider transaction that took place on Jun 20 ’25, was worth 269,625. Before that another transaction happened on Jun 17 ’25, when Company’s PRESIDENT AND CEO sold 12,500 for $22.18, making the entire transaction worth $277,292. This insider now owns 952,892 shares in total.
Enliven Therapeutics Inc (ELVN) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -15.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -24.58% during the next five years compared to 19.02% growth over the previous five years of trading.
Enliven Therapeutics Inc (NASDAQ: ELVN) Trading Performance Indicators
You can see what Enliven Therapeutics Inc (ELVN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 21.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.93, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach -2.61 in one year’s time.
Technical Analysis of Enliven Therapeutics Inc (ELVN)
Looking closely at Enliven Therapeutics Inc (NASDAQ: ELVN), its last 5-days average volume was 0.7 million, which is a jump from its year-to-date volume of 0.34 million. As of the previous 9 days, the stock’s Stochastic %D was 45.22%.
During the past 100 days, Enliven Therapeutics Inc’s (ELVN) raw stochastic average was set at 64.66%, which indicates a significant increase from 31.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.17% in the past 14 days, which was higher than the 73.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.82, while its 200-day Moving Average is $22.28. However, in the short run, Enliven Therapeutics Inc’s stock first resistance to watch stands at $20.99. Second resistance stands at $21.69. The third major resistance level sits at $22.07. If the price goes on to break the first support level at $19.90, it is likely to go to the next support level at $19.52. Should the price break the second support level, the third support level stands at $18.82.
Enliven Therapeutics Inc (NASDAQ: ELVN) Key Stats
There are 49,069K outstanding shares of the company, which has a market capitalization of 1.20 billion. As of now, sales total 0 K while income totals -89,020 K. Its latest quarter income was 0 K while its last quarter net income were -28,540 K.
